MX2023001740A - Metodos de tratamiento de la gota. - Google Patents

Metodos de tratamiento de la gota.

Info

Publication number
MX2023001740A
MX2023001740A MX2023001740A MX2023001740A MX2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A MX 2023001740 A MX2023001740 A MX 2023001740A
Authority
MX
Mexico
Prior art keywords
methods
treating gout
pegylated uricase
mtx
administering
Prior art date
Application number
MX2023001740A
Other languages
English (en)
Spanish (es)
Inventor
Paul Peloso
Brian Lamoreaux
Swarnendra Verma
Original Assignee
Horizon Therapeutics Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Usa Inc filed Critical Horizon Therapeutics Usa Inc
Publication of MX2023001740A publication Critical patent/MX2023001740A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y107/00Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Glass Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023001740A 2020-08-10 2021-08-10 Metodos de tratamiento de la gota. MX2023001740A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063826P 2020-08-10 2020-08-10
US202163148982P 2021-02-12 2021-02-12
PCT/US2021/045350 WO2022035828A1 (en) 2020-08-10 2021-08-10 Methods of treating gout

Publications (1)

Publication Number Publication Date
MX2023001740A true MX2023001740A (es) 2023-04-05

Family

ID=80247297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001740A MX2023001740A (es) 2020-08-10 2021-08-10 Metodos de tratamiento de la gota.

Country Status (11)

Country Link
US (2) US20230301999A1 (https=)
EP (2) EP4588513A3 (https=)
JP (1) JP2023537403A (https=)
KR (1) KR20230086660A (https=)
CN (1) CN116261463A (https=)
AU (1) AU2021324665A1 (https=)
BR (1) BR112023002458A2 (https=)
CA (1) CA3189100A1 (https=)
IL (1) IL300536A (https=)
MX (1) MX2023001740A (https=)
WO (1) WO2022035828A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG161247A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP4588513A3 (en) * 2020-08-10 2025-10-22 Horizon Therapeutics USA, Inc. Methods of treating gout
WO2024088213A1 (en) * 2022-10-24 2024-05-02 Westlake Therapeutics (Shanghai) Co., Limited Combination to induce specific immune tolerance
US12201413B2 (en) 2023-03-01 2025-01-21 Washington University Free breathing dynamic contrast enhanced (DCE) liver MR imaging
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000008196A2 (en) * 1998-08-06 2000-02-17 Duke University Urate oxidase
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
SG161247A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク. 陽イオン界面活性剤によるタンパク質の精製
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
KR20180120753A (ko) * 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
ES3036482T3 (en) * 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2020160325A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160324A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP4588513A3 (en) * 2020-08-10 2025-10-22 Horizon Therapeutics USA, Inc. Methods of treating gout

Also Published As

Publication number Publication date
CA3189100A1 (en) 2022-02-17
EP4588513A2 (en) 2025-07-23
BR112023002458A2 (pt) 2023-05-02
AU2021324665A1 (en) 2023-04-13
CN116261463A (zh) 2023-06-13
WO2022035828A1 (en) 2022-02-17
IL300536A (en) 2023-04-01
KR20230086660A (ko) 2023-06-15
JP2023537403A (ja) 2023-08-31
US20220323445A1 (en) 2022-10-13
EP4588513A3 (en) 2025-10-22
EP4192581A1 (en) 2023-06-14
US20230301999A1 (en) 2023-09-28
EP4192581A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
MX2023001740A (es) Metodos de tratamiento de la gota.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2003037313A3 (en) Methods for the treatment of addiction
MXPA06000619A (es) Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
WO2004046196A3 (en) Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
MXPA05000880A (es) Probioticos para funciones neuromusculares del intestino.
HUS1300069I1 (hu) Dextrometorfánt és kinidint tartalmazó gyógyászati készítmények neurológiai rendellenességek kezelésére
HUP0303927A2 (hu) Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre
IL165858A (en) Pharmaceutical preparation for treating human malignancies with arginine deprivation and uses thereof
MX2023001140A (es) Uso del dexpramipexol para el tratamiento de asma moderado a grave.
MY125984A (en) Pharmaceutical solutions of levosimendan.
MX2023010774A (es) Pauta posologica de sotorasib.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
TW200630089A (en) Treatment methods
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
AP1896A (en) The method of treating cancer
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
IL159770A0 (en) Calcium salts with cytotoxic activity
MX2023006294A (es) Proteinas de union a il-7 y su uso en tratamientos medicos.
WO2004045497A3 (en) Cd26-based therapies for cancers and immune disease
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy